Tafluprost
 | |
| Systematic (IUPAC) name | |
|---|---|
|
isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-en-1-yl]-3,5-dihydroxycyclopentyl}hept-5-enoate | |
| Clinical data | |
| Trade names | Saflutan, Taflotan, Tapros, Zioptan |
| AHFS/Drugs.com | International Drug Names |
| Pregnancy category |
|
| Routes of administration | Topical (eye drops) |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | 209860-87-7 |
| ATC code | S01EE05 (WHO) |
| PubChem | CID 6433101 |
| ChemSpider | 8044182 |
| UNII |
1O6WQ6T7G3  |
| ChEBI |
CHEBI:66899 |
| ChEMBL | CHEMBL1963683 |
| Chemical data | |
| Formula | C25H34F2O5 |
| Molar mass | 452.531266 g/mol |
| |
| |
Tafluprost (trade names Taflotan, marketed by Santen Pharmaceutical and Zioptan, by Merck (U.S.)) is a prostaglandin analogue used topically (as eye drops) to control the progression of glaucoma and in the management of ocular hypertension. It reduces intraocular pressure by increasing the outflow of aqueous fluid from the eyes.[1][2]
Taflotan contains 15 µg/ml Tafluprost. Taflotan sine is a preservative-free, single-dose formulation containing 0.3 ml per dose.[3]
References
- ↑ Schubert-Zsilavecz, M, Wurglics, M, Neue Arzneimittel 2008/2009
- ↑ Santen Home Page
- ↑ Gelbe Liste (in German)
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ||||||||||||||||||||||||||||||||||||
4. Sethi HS, Dhawan M, Naik MP, Gupta VS. Prostaglandin analogs in glaucoma. Astrocyte 2015;2:126-32.
This article is issued from Wikipedia - version of the Monday, May 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.